• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Estring (estradiol vaginal ring) August 2008


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- August 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.


Summary View

Sections Modified

ADVERSE REACTIONS

  • Postmarketing Experience
    • A few cases of toxic shock syndrome (TSS) have been reported...
    • A few cases of ring adherence to the vaginal wall, making ring removal difficult, have been reported...
    • A few cases of bowel obstruction and vaginal ring use have been reported...

PATIENT PACKAGE INSERT

  • Who should not use Estring?
    • Currently have or have had liver problems.
  • What are the possible side effects of Estring?
    • Initial Paragraph
  • What can I do to lower my chances of getting a serious side effect with Estring?